EyePoint Pharmaceuticals (EYPT)
0.43
0.00 (0.00%)
Upcoming Events
Latest Headlines
Laidlaw Downgrades EyePoint Inc. (EYPT) to Hold
October 20, 2026 8:44 AM - StreetInsider
EyePoint Inc. (EYPT) PT Lowered to $1 at RBC Capital
October 20, 2026 5:50 AM - StreetInsider
Mizuho Downgrades EyePoint Inc. (EYPT) to Neutral 'on Negative P3 Data, Lack of Catalysts, Financing Overhang'
October 20, 2026 5:31 AM - StreetInsider
JPMorgan Downgrades EyePoint Inc. (EYPT) to Underweight
October 20, 2026 3:33 AM - StreetInsider
Guggenheim Downgrades EyePoint Inc. (EYPT) to Neutral
October 19, 2026 12:50 PM - StreetInsider
Jefferies Downgrades EyePoint Inc. (EYPT) to Hold
October 19, 2026 10:00 AM - StreetInsider
EyePoint crashes as pivotal wet AMD trial fails, prompting 53% workforce cut
October 19, 2026 9:38 AM - StreetInsider
Form 8-K EyePoint, Inc. For: Oct 17
October 19, 2026 9:22 AM - SEC Filing
EyePoint cuts 53% of workforce after wet AMD trial failure
October 19, 2026 7:16 AM - StreetInsider
EyePoint Announces Strategic Prioritization
October 19, 2026 7:15 AM - Globe NewsWire
Form 8-K EyePoint, Inc. For: Oct 19
October 19, 2026 7:05 AM - SEC Filing
EyePoint's Duravyu fails primary endpoint in second wet AMD trial
October 19, 2026 7:00 AM - StreetInsider
EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD
October 19, 2026 7:00 AM - Globe NewsWire
EyePoint Pharmaceuticals Halted, News Pending
October 19, 2026 6:57 AM - StreetInsider
Form SCHEDULE 13G/A EyePoint, Inc. Filed by: FEDERATED HERMES, INC.
October 7, 2026 7:23 AM - SEC Filing
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
September 16, 2026 7:00 AM - Globe NewsWire
Form 8-K EyePoint, Inc. For: Sep 10
September 10, 2026 7:06 AM - SEC Filing
TD Cowen Downgrades EyePoint Inc. (EYPT) to Hold
September 2, 2026 2:04 AM - StreetInsider
Form 4 EyePoint, Inc. For: Aug 20 Filed by: Elston George
August 24, 2026 4:11 PM - SEC Filing
Form 4 EyePoint, Inc. For: Aug 18 Filed by: Zaderej Karen L.
August 18, 2026 4:09 PM - SEC Filing
EyePoint Pharmaceuticals (EYPT) call put ratio 1.4 calls to 1 put as share price up 8.9%
August 18, 2026 1:27 PM - StreetInsider
Chardan Downgrades EyePoint Inc. (EYPT) to Neutral
August 18, 2026 8:11 AM - StreetInsider
H.C. Wainwright Downgrades EyePoint Inc. (EYPT) to Neutral
August 18, 2026 6:09 AM - StreetInsider
RBC Capital Downgrades EyePoint Inc. (EYPT) to Sector Perform
August 18, 2026 2:52 AM - StreetInsider
EyePoint Inc. (EYPT) PT Lowered to $48 at Laidlaw
August 17, 2026 3:24 PM - StreetInsider
Guggenheim Reiterates Buy Rating on EyePoint Inc. (EYPT)
August 17, 2026 1:01 PM - StreetInsider
JPMorgan Downgrades EyePoint Inc. (EYPT) to Neutral
August 17, 2026 12:51 PM - StreetInsider
EyePoint Inc. (EYPT) PT Lowered to $8 at Jefferies
August 17, 2026 12:31 PM - StreetInsider
Stifel on EyePoint Inc. (EYPT): 'we think these data bode well for LUCIA (expected October) barring another unusual asymmetry'
August 17, 2026 12:07 PM - StreetInsider
Cantor Fitzgerald Downgrades EyePoint Inc. (EYPT) to Neutral
August 17, 2026 9:30 AM - StreetInsider
Form 8-K EyePoint, Inc. For: Aug 17
August 17, 2026 8:51 AM - SEC Filing
Citi cuts EyePoint price target to $17 from $35, keeps Buy, stock down 67%
August 17, 2026 8:41 AM - StreetInsider
EyePoint's DURAVYU misses primary endpoint in wet AMD trial
August 17, 2026 7:01 AM - StreetInsider
EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD
August 17, 2026 7:00 AM - Globe NewsWire
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 14, 2026 4:33 PM - Globe NewsWire
Form SCHEDULE 13G/A EyePoint, Inc. Filed by: Cormorant Asset Management, LP
August 14, 2026 2:03 PM - SEC Filing
Form SCHEDULE 13G EyePoint, Inc. Filed by: Adage Capital Management, L.P.
August 12, 2026 12:02 PM - SEC Filing
EyePoint Inc. (EYPT) PT Lowered to $27 at H.C. Wainwright
August 6, 2026 6:55 AM - StreetInsider
Form S-8 EyePoint, Inc.
August 5, 2026 4:24 PM - SEC Filing
Form 10-Q EyePoint, Inc. For: Jun 30
August 5, 2026 4:07 PM - SEC Filing
Form 8-K EyePoint, Inc. For: Aug 05
August 5, 2026 7:06 AM - SEC Filing
EyePoint Pharmaceuticals (EYPT) Misses Q2 EPS by 15c
August 5, 2026 7:05 AM - StreetInsider
EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
August 5, 2026 7:00 AM - Globe NewsWire
Citi opens 90-day upside catalyst call on EyePoint
August 5, 2026 6:31 AM - StreetInsider
Form SCHEDULE 13G EyePoint, Inc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC
July 31, 2026 10:19 AM - SEC Filing
Form 8-K EyePoint, Inc. For: Jul 30
July 30, 2026 7:05 AM - SEC Filing
EyePoint completes enrollment in two phase 3 DME drug trials
July 30, 2026 7:01 AM - StreetInsider
EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)
July 30, 2026 7:00 AM - Globe NewsWire
EyePoint Inc. (EYPT) PT Raised to $39 at Mizuho, 'Top Pick'
July 29, 2026 6:53 AM - StreetInsider
Form SCHEDULE 13G/A EyePoint, Inc. Filed by: BlackRock, Inc.
July 28, 2026 4:46 PM - SEC Filing
Full Article List
